Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT): Price and Financial Metrics


Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT)

Today's Latest Price: $4.38 USD

0.08 (-1.79%)

Updated Jan 25 8:20am

Add OSMT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OSMT Stock Summary

  • OSMT's went public 2.27 years ago, making it older than just 5.04% of listed US stocks we're tracking.
  • With a year-over-year growth in debt of -18.71%, Osmotica Pharmaceuticals plc's debt growth rate surpasses merely 15.84% of about US stocks.
  • Revenue growth over the past 12 months for Osmotica Pharmaceuticals plc comes in at -17.31%, a number that bests just 20.85% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Osmotica Pharmaceuticals plc, a group of peers worth examining would be ORBC, LIVN, SANW, OPK, and CMTL.
  • OSMT's SEC filings can be seen here. And to visit Osmotica Pharmaceuticals plc's official web site, go to www.osmotica.com.

OSMT Stock Price Chart Interactive Chart >

Price chart for OSMT

OSMT Price/Volume Stats

Current price $4.38 52-week high $9.67
Prev. close $4.46 52-week low $2.81
Day low $4.38 Volume 846
Day high $4.38 Avg. volume 487,690
50-day MA $5.33 Dividend yield N/A
200-day MA $5.47 Market Cap 274.12M

Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio


Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.

OSMT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$4.38$0.21 -95%

We started the process of determining a valid price forecast for Osmotica Pharmaceuticals plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 8th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:

  • Interest coverage, a measure of earnings relative to interest payments, is -2.22; that's higher than only 15.73% of US stocks in the Healthcare sector that have positive free cash flow.
  • Its compound free cash flow growth rate, as measured over the past 2.11 years, is -0.31% -- higher than merely 5.08% of stocks in our DCF forecasting set.
  • 56% of the company's capital comes from equity, which is greater than merely 24.6% of stocks in our cash flow based forecasting set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-95%
1%-95%
2%-95%
3%-95%
4%-95%
5%-95%

Want more companies with a valuation profile/forecast similar to that of Osmotica Pharmaceuticals plc? See COO, NVST, TEVA, BHC, and EW.


OSMT Latest News Stream


Event/Time News Detail
Loading, please wait...

OSMT Latest Social Stream


Loading social stream, please wait...

View Full OSMT Social Stream

Latest OSMT News From Around the Web

Below are the latest news stories about Osmotica Pharmaceuticals plc that investors may wish to consider to help them evaluate OSMT as an investment opportunity.

Is Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Popular Amongst Institutions?

A look at the shareholders of Osmotica Pharmaceuticals plc ( NASDAQ:OSMT ) can tell us which group is most powerful...

Yahoo | January 12, 2021

Osmotica Pharmaceuticals plunges 27% on FDA response letter

The FDA has issued a complete response letter ((CRL)) regarding Osmotica Pharmaceuticals (OSMT) new drug application for arbaclofen extended release tablets to treat spasticity resulting from multiple sclerosis. The CRL stated that the Company did not provide adequate justification (including in its most recent NDA amendment) for the statistical analysis of...

Seeking Alpha | December 30, 2020

Osmotica price target cut at SVB Leerink after FDA snub; retains outperform rating

Osmotica Pharmaceuticals (OSMT) has lost 20.8% today so far, as SVB Leerink cut its price target after the company announced the receipt of the Complete Response Letter from the FDA for its arbaclofen extended-release tablets to treat spasticity resulting from multiple sclerosis.The new price target of $7 down from the previous $10 reflects...

Seeking Alpha | December 30, 2020

Osmotica Tanks 25% As FDA Requests Efficacy Study For Arbaclofen

Shares of Osmotica Pharmaceuticals plunged 25% in Tuesday's after-market trading after the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) for Arbaclofen. Osmotica's (OSMT) NDA was expected to show the clinical efficacy and safety of arbaclofen tablets used in the treatment for patients with spasticity due to multiple sclerosis. Spasticity refers to the condition of stiffening muscles thereby affecting movement, speech and gait.

Anusuya Lahiri on TipRanks | December 30, 2020

Why Osmotica Pharmaceuticals Stock Plunged Today

Shares of Osmotica Pharmaceuticals (NASDAQ: OSMT), a biopharmaceutical company, dropped by as much as 24.4% on Wednesday and closed today's trading session down by 20%. Investors sold off shares of the company following its announcement that the U.S. Food and Drug Administration (FDA) has declined to approve one of its products. Osmotica Pharmaceuticals submitted an amended New Drug Application (NDA) for Arbaclofen ER, a potential treatment for spasticity associated with Multiple Sclerosis (MS), on June 30.

Yahoo | December 30, 2020

Read More 'OSMT' Stories Here

OSMT Price Returns

1-mo N/A
3-mo -21.51%
6-mo -16.09%
1-year -37.43%
3-year N/A
5-year N/A
YTD 6.31%
2020 -41.06%
2019 -9.81%
2018 N/A
2017 N/A
2016 N/A

Continue Researching OSMT

Want to see what other sources are saying about Osmotica Pharmaceuticals plc's financials and stock price? Try the links below:

Osmotica Pharmaceuticals plc (OSMT) Stock Price | Nasdaq
Osmotica Pharmaceuticals plc (OSMT) Stock Quote, History and News - Yahoo Finance
Osmotica Pharmaceuticals plc (OSMT) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9459 seconds.